|
Dr. Gilles Amsallem,
CEO, has 20 years experience in numerous areas of
biotechnology and acquired
scientific, industrial and
financial expertise at Litton
Bionetics, DuPont, Sorin
Biomedica, SNIA, Biocon and
Avesthagen. He also was the
founder and CEO of Mixis
Genetics later acquired by
Pfizer.
Anthony Scime
Optafuel US CEO, has over 10 years experience
in investment ($ 80 million in
management) and financial
strategy at Bausch & Lomb.
Dr. Bruno Winter,
CSO (Cellulase and Biocatalysts Expert), has over 15
years experience in management
of R & D. He is the former
Global Director of R & D at AB
Enzymes GmbH.
Niels Langvad,
CTO
(Process & Pilot) has an experience of over 20 years in the
chemical industry and energy
sector. Co-founder of biodiesel
ApS, spin-off from the Danish
Ecole Polytechnique, he led the
design and construction of its
biorefinery pilot plant and he
then led the installation of a
demonstration plant for 2nd
generation biofuels in USA . He
is a member of several
committees in the strategic
field of bioenergy, including
European Biofuels Technology
Platform Work, as well as a
member of the Board of BioEnergy
DI (Danish Industry Association,
Denmark).
Dr. Stéphane Blesa,
COO (Strains
development & Enzymology) the first employee of Biométhodes, is a
specialist in molecular
evolution. He served as project
manager and technical director
for projects in the areas of
biocatalysis, enzymology and
engineering of therapeutic
proteins amongst others.
Raffy Kazandjian
CFO, has over 20 years experience in venture capital in biotechnology in
Europe, the United States and
Canada. He is the former
president of CDC-Innovation
Partners.
Romain Fouache,
Corporate Development, is experienced in
valorization of disruptive
innovation and building of a
partner ecosystem.
Biométhodes is organized as a
limited company with a Board
composed of:
- Gilles Amsallem,
CEO, Biométhodes
- Robert Leon,
permanent representative of the
company TALIS,
- Stéphane Andre, permanent representative of
the company SOCHRASTEM.
|
